

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Viral infection	Not applicable	<p>Cell culture and rodent studies suggest squalamine could be a broad-spectrum antiviral. In human cell culture, squalamine inhibited dengue virus, HBV and hepatitis-δ virus infection compared with no treatment. In hamsters infected with yellow fever virus or eastern equine encephalitis virus, squalamine increased survival compared with vehicle. Next steps include advancing squalamine to clinical trials for viral infection.</p> <p>Ohr Pharmaceutical Inc.'s Evizon squalamine is in Phase II trials for ovarian cancer and Phase III testing for age-related macular degeneration (AMD) and choroidal neovascularization (CNV).</p> <p>SciBX 4(39); doi:10.1038/scibx.2011.1090 Published online Oct. 6, 2011</p>	<p>Several patent applications filed for treating and preventing viral infections and for squalamine formulations and commercial synthesis; available for partnering through Zasloff Laboratories LLC</p> <p>Contact: Michael Zasloff, Zasloff Laboratories LLC, Doylestown, Pa. e-mail: mzasloff@zaslabs.com</p>	<p>Zasloff, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Sept. 20, 2011; doi:10.1073/pnas.1108558108</p> <p>Contact: Michael Zasloff, Georgetown University Medical Center, Washington, D.C. e-mail: maz5@georgetown.edu</p>